Login | Register
Profile | Log out
logo

  • Home
  • News
  • Opinion
  • Other
    • Market Updates
    • Explainers
    • Satire
  • About
  • Contact Us
    • Contact
    • Get Covered
    • Posting Guidelines
  • Subscribe
Submit An Article

biotech

  • Home
  •  
  • biotech



  • Most Read
  • Latest Comments
  • Aussie cancer researcher primed for 2023 with groundbreaking clinical trial data releases scheduled
    • News

    RBA and ASIC up the ante on blockchain project, ASX writes off millions
    Public
  • Aussie cancer researcher primed for 2023 with groundbreaking clinical trial data releases scheduled
    • Satire

    Australia to close borders to Omicron Persei 8
    Public
  • Aussie cancer researcher primed for 2023 with groundbreaking clinical trial data releases scheduled
    • Opinion

    The New Criterion: will the listed sanitiser stocks clean up – or clean out – investors?
    Public
  • Aussie cancer researcher primed for 2023 with groundbreaking clinical trial data releases scheduled
    • Opinion

    Is this the most hated company on the ASX?
    Public
  • Aussie cancer researcher primed for 2023 with groundbreaking clinical trial data releases scheduled
    Opening a new frontier in treating Parkinson’s disease
    • Review
    • November 11, 2022
  • Tremors from the FTX collapse continue to be felt as DigitalX sells off 15% Bitcoin holdings
    • Review
    • January 10, 2023
  • AUDC stablecoin gathers momentum as Novatti confirms integration with XRP Ledger
    • Review
    • June 9, 2022
  • PharmAust completes dosing first cohort for MND treatment, patients respond positively
    • Review
    • January 6, 2023
  • Is this the most hated company on the ASX?
    • Review
    • August 16, 2019

Latest Articles

  • Imagion Biosystems Advances MagSense® Phase 2 Trial
    Imagion Biosystems Advances MagSense® Phase 2 Trial
    • News

  • Acrux-developed Menopause Hormone Therapy to enter Australian market
    Acrux-developed Menopause Hormone Therapy to enter Australian market
    • News

  • Actinogen’s Phase 2a clinical trial for depression treatment fails to meet primary endpoint, shares tank
    Actinogen’s Phase 2a clinical trial for depression treatment fails to meet primary endpoint, shares tank
    • News

  • Holista Colltech banks on new partners to turn fortunes as food sales struggle
    Holista Colltech banks on new partners to turn fortunes as food sales struggle
    • News

  • Zelira Therapeutics nears clinical trial stage for Autism drug following positive FDA feedback
    Zelira Therapeutics nears clinical trial stage for Autism drug following positive FDA feedback
    • News

  • Aussie cancer researcher primed for 2023 with groundbreaking clinical trial data releases scheduled
    • News

    Aussie cancer researcher primed for 2023 with groundbreaking clinical trial data releases scheduled

    Aussies are some of the most enthusiastic adopters of new clinical drugs. In 2019, 95,000 of us participated in nearly 2,000 clinical trials where Australia is home to many of the world’s leading scientists. In keeping with that, clinical stage biotech company Pharmaxis (ASX: PXS) has a thriving drug development pipeline set to report clinical

    Read More
    Public
  • Pharmaxis cancer drug progress detailed at leading scientific conference, eyes FDA discussions in 2023
    • News

    Pharmaxis cancer drug progress detailed at leading scientific conference, eyes FDA discussions in 2023

    Having delivered impressive interim trial data from their Phase 2 clinical trials for a treatment targeting incurable bone marrow cancer, the US Food & Drug Administration (FDA) could soon be the next stop for biopharmaceuticals company Pharmaxis (ASX: PXS) fresh off their poster presentation at the American Society of Hematology (ASH) conference.  Hosted in New

    Read More
    Public
  • Platinum Asset Management identify value opportunity in Pharmaxis with $1.9m stake
    • News

    Platinum Asset Management identify value opportunity in Pharmaxis with $1.9m stake

    When it comes to biotech investing, the value opportunities in Australia attract many of the world’s smartest investors. Amongst them, Platinum Asset Management (ASX: PTM) has joined a growing list of institutions taking a substantial stake in a little-known Aussie biotech set to announce hugely-anticipated clinical trial results within the next few months.  With more

    Read More
    Public
  • The age of mRNA therapeutics is now – with exosomes
    • Opinion

    The age of mRNA therapeutics is now – with exosomes

    mRNA therapeutics are now expected to become the third major class of drugs. But converting their promise into reality, just like what happened with electric vehicles, is not without technical challenges. In the case of electric vehicles, their sales only really took off once the complex new battery technologies which enabled high-performance together with extended

    Read More
    Public
  • Cynata teams up with Leiden University Medical Center to test its stem cell solution on kidney transplant patients
    • News

    Cynata teams up with Leiden University Medical Center to test its stem cell solution on kidney transplant patients

    For the past few years, stem cells have come out on top as a reliable solution to many health concerns, from diabetes to cancer. Clinical stage BioTech company Cynata Therapeutics (ASX: CYP) has been testing stem cell therapy for kidney transplant patients. The Company announced that Leiden University Medical Center (LUMC) is funding an important

    Read More
    Public
  • Not getting enough shut eye? Medibio opens new trial looking at sleep disturbances and mental health factors
    • News

    Not getting enough shut eye? Medibio opens new trial looking at sleep disturbances and mental health factors

    (Not so) fun fact for your Thursday morning: sleep deprivation was (and I’m sure, still is) used as a form of torture.  One of the “enhanced interrogation techniques” the CIA used in the wake of the 9/11 terrorist attacks was just that. Lack of sleep disrupts biological functions deep in the brain. Whilst not as

    Read More
    Public
  • «
  • ‹
  • 3
  • 4
  • 5
  • 6
  • 7
  • ›
  • »

Login or register for free to access unlimited reading

Register Now!
  • News

  • Opinion

  • Satire

  • About

  • Contact Us

  • Subscribe

The content published on this website is solely for general information purposes and is not to be construed as financial advice. Should you seek financial advice you should consult with an appropriately qualified person. Opinions expressed on this site are subject to change without notice and The Sentiment who produced this content is under no obligation to keep the information current. The Sentiment, affiliated companies & associates may have a conflict of interest with companies discussed on the website due to commercial arrangements, for example they may be shareholders in the company, be engaged by them to assist in investor communications or receive commission/brokerage for funds raised.

Copyright © 2020 The Sentiment. All rights reserved.
Subscribe

Enter your email address below to subscribe to The Sentiment’s weekly newsletter, highlighting the top news, research, opinion and satire articles shaping ASX investor sentiment.

The Sentiment respects your privacy and will not spam you. View our privacy policy here.